Novavax reported $2.35B in Current Assets for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Adamas Pharmaceuticals ADMS:US 115.66M 42.45M
Adma Biologics ADMA:US $ 171.36M 5.92M
Agenus AGEN:US $ 92.85M 42.81M
AstraZeneca AZN:LN 27.27B 8.54B
Astrazeneca AZN:US 27.27B 8.54B
BioSpecifics Technologies BSTC:US 102.07M 9.99M
Dynavax Technologies DVAX:US $ 583.91M 156.37M
Genocea Biosciences GNCA:US $ 62.91M 5.91M
Geron GERN:US $ 201.76M 13.5M
GlaxoSmithKline GSK:LN 17.57B 958M
Kindred Biosciences KIN:US 79.08M 8K
Mannkind MNKD:US $ 179.9M 108.44M
Minerva Neurosciences NERV:US $ 75.22M 6.46M
Moderna Inc MRNA:US 10.97B 734M
Novartis NVS:US $ 23808M 1610M
Novavax NVAX:US $ 2354.99M 108.21M
Pain Therapeutics PTIE:US $ 279.56M 4.21M
Peregrine Pharmaceuticals PPHM:US $ 200.78M 7.02M
Sarepta Therapeutics SRPT:US $ 2265.22M 6.13M